AdvanTIG-205: Ociperlimab and Tislelizumab as First-Line Treatment in the Metastatic Setting
Condition: Non-Small Cell Lung Cancer
Sponsor: BeiGene, Ltd.
Full Title
AdvanTIG-205: A Phase 2, Randomized, Double-blind Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Sensitizing EGFR or ALK Mutations who have Received No Previous Treatment for Metastatic Disease
Eligibility
Ociperlimab and Tislelizumab in the first line setting for patients with stage IV squamous or non-squamous non-small cell lung cancer.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
